The frequency of each genomic aberration of our study was not significantly different from previously reported representative results of The Cancer Genome Atlas glioma cohort [19,20,21] (Figure 4), except for the relatively higher frequency of genetic aberrations in BRAF and FGFRs. The gene discussed is BRAF; the disease is central nervous system cancer.